Insomnia

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

Retrieved on: 
Thursday, September 12, 2024
Psychotherapy, FDA, Al-Quds, Therapy, Insomnia, Social support, Quality of life, Anxiety, DSM-IV codes, Hebrew University of Jerusalem, Weight gain, Nausea, Post-traumatic stress disorder, PTSD, Patent, Pharmaceutical industry

Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the submission of a patent application under the International Patent Cooperation Treaty (“PCT”). This submission is part of the Company’s ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), pursuant to the exclusive licensing agreement Clearmind holds with Yissum.

Key Points: 
  • This submission is part of the Company’s ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”), pursuant to the exclusive licensing agreement Clearmind holds with Yissum.
  • The patent application covers innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel of the Hebrew University.
  • Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “Our collaboration with Yissum continues to yield remarkable results.
  • Our goal is to deliver effective and safe treatments for PTSD, such as our next-generation psychedelic compounds, which aim to significantly improve the quality of life for patients.”

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

Retrieved on: 
Wednesday, September 11, 2024
Itch, Asthma, Regeneron Pharmaceuticals, Research, Patient, Aes, OCS, Safety, FDA, Infection, Skin, Disease, Arthralgia, Dermatology, Insomnia, Food, Death, Blurred vision, Hypertension, Back pain, Constipation, Peripheral edema, Mortality, Upper respiratory tract infection, ADEPT, Rash, Blister, Bleeding, Orphan, Conjunctivitis, BP, Pharmaceutical industry

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the trial, five times more Dupixent patients achieved sustained disease remission compared to those on placebo. Sustained disease remission was defined as complete clinical remission with completion of oral corticosteroids (OCS) taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period. Dupixent was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for BP, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. This trial will support regulatory submissions around the world, starting with the U.S. later this year.

Key Points: 
  • In the trial, five times more Dupixent patients achieved sustained disease remission compared to those on placebo.
  • This trial will support regulatory submissions around the world, starting with the U.S. later this year.
  • BP, a chronic and relapsing disease, is characterized by intense itch and blisters, reddening of the skin and painful chronic lesions.
  • “Bullous pemphigoid is a debilitating skin disease with a high mortality rate due to infection.

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Retrieved on: 
Wednesday, September 11, 2024
Itch, Asthma, Research, Patient, Aes, OCS, Safety, Infection, Skin, Disease, IL13, Dermatology, Arthralgia, Insomnia, Food, Death, Blurred vision, Hypertension, Back pain, Constipation, Peripheral edema, Mortality, Upper respiratory tract infection, BP, Inflammation, ADEPT, Rash, Blister, Bleeding, Orphan, Conjunctivitis, IL4, Pharmaceutical industry

A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease.

Key Points: 
  • A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease.
  • In the study, five times more Dupixent patients achieved sustained disease remission compared to those on placebo.
  • This study will support regulatory submissions around the world, starting with the U.S. later this year.
  • BP, a chronic and relapsing disease, is characterized by intense itch and blisters, reddening of the skin, and painful chronic lesions.

DM Clinical Research Partners with Brain and Pain Care and Sleep Care Clinic for New Shreveport Site

Retrieved on: 
Tuesday, September 10, 2024
Sleep apnea, Research, University, Patient, Spartan Health Sciences University, Sleep, Pain management, Insomnia, Neuropathic pain, Migraine, Health, Partnership, Guntur Medical College, Arthritis, Headache, Brain, Interventional pain management, Medical device

This collaboration is part of DM Clinical Research's continuing efforts to advance medical research and offer more opportunities for patients to participate in cutting-edge clinical trials.

Key Points: 
  • This collaboration is part of DM Clinical Research's continuing efforts to advance medical research and offer more opportunities for patients to participate in cutting-edge clinical trials.
  • Dr. Munjampalli's practice, Brain and Pain Care, along with Dr. Samreena's Sleep Care Clinic, which operates within the same facility, will now house an embedded clinical research site, expanding the reach of DM Clinical Research in the region.
  • "We are excited to partner with Dr. Munjampalli and Dr. Samreena, whose dedication to patient care and medical research aligns perfectly with our mission," said Mohammad Millwala, CEO of DM Clinical Research.
  • With this new embedded site in Shreveport, DM Clinical Research continues to build a strong network of research sites nationwide, enhancing its ability to offer diverse and inclusive clinical trials.

No-sleep challenge: the dangers of sleep deprivation

Retrieved on: 
Tuesday, September 10, 2024
Shift, Irritability, Sleep deprivation, Insomnia, Hallucination, Parasympathetic nervous system, Guinness, Guinness World Records, Safety, Heart rate, Rest, Brain, Fatigue, Obesity, Dementia, Depression, Death, Stroke, REM, Health, Diabetes, Hypertension, Sleep, Social media, Learning, Weight gain, Digestion, Memory, Sleep hygiene, Risk, Caffeine, Creativity, Blood pressure, Pharmaceutical industry

In 1997, Guinness World Records stopped monitoring the record for the longest time without sleep for safety reasons – and they were quite right.

Key Points: 

  • In 1997, Guinness World Records stopped monitoring the record for the longest time without sleep for safety reasons – and they were quite right.

  • Going without sleep for extended periods of time can prove extremely dangerous.

    Adults should aim for more than seven hours’ sleep per night on a regular basis.

  • Alcohol or caffeine consumption prior to bed can disturb these sleep cycles.

    Sleep deprivation can be acute or chronic.

  • However, studies have shown that recovery sleep often doesn’t reverse the metabolic changes that can cause weight gain and a decrease in insulin sensitivity, even from relatively short periods of sleep deprivation.

U.S. Sleep Disorders Treatment Market Report 2024: Sleep Centers, Sleep Studies & CPAPs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 10, 2024
Health, Other Health, COVID-19, Sleep apnea, Bed, Patient, Prevalence, CDC, Medicare, Sleep disorder, Address, Insomnia, National Sleep Foundation, Data Axle, Sleep, NSF, CPAP, Sale, MD, Pharmaceutical industry

Data/surveys from the National Sleep Foundation, American Society of Sleep Medicine, Sleep Review, brokerage firms, CDC, Centers for Medicare Services, etc.

Key Points: 
  • Data/surveys from the National Sleep Foundation, American Society of Sleep Medicine, Sleep Review, brokerage firms, CDC, Centers for Medicare Services, etc.
  • of sleep disorders, description of most common sleep disorders, NSF vs. other polls.
  • Nature of the field of sleep medicine and somnology: history/evolution of sleep centers, number, multiple-site chains, mkt.
  • size 1997-2028F
    Extensive list of sleep disorder statistics: use of sleep aids, people with sleep apnea, etc.

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

Retrieved on: 
Monday, September 9, 2024
Epilepsy, International League Against Epilepsy, Congress, Diagnosis, Insomnia, UCB, ILAE, Prognosis, Life, Lennox–Gastaut syndrome, Sleep disorder, DSP, Attention deficit hyperactivity disorder, Seizure, Deficit spending, Patient, ADHD, Comorbidity, Physician, LGS, Nursing

At UCB, we understand the need for a multidisciplinary, individualized approach to care which addresses each patient's medical, educational, psychological, and social needs throughout the course of their life."

Key Points: 
  • At UCB, we understand the need for a multidisciplinary, individualized approach to care which addresses each patient's medical, educational, psychological, and social needs throughout the course of their life."
  • [2]
    Although several approved drugs are available for LGS, there are still unmet needs for treatment.
  • The questionnaire considers the mandatory, alert, and exclusionary features of LGS, providing a result that will guide future management.
  • The prototype will now be tested and validated prior to use by healthcare professionals in the clinical setting.

Waking up with a bang? It could be ‘exploding head syndrome’

Retrieved on: 
Wednesday, September 4, 2024
Sleep, Head, Noise, Voice of the Beehive, Hypothalamus, EHS, Pain, Hallucination, Parasomnia, Mindfulness, Brain, Wakefulness, Reticular formation, Headache, Education, Prevalence, Insomnia, Sleep paralysis, Sound, Fear, Human, Sensation, Environment, Pharmaceutical industry

If you have, then you have most likely experienced exploding head syndrome, a mysterious and poorly understood sleep disorder.

Key Points: 
  • If you have, then you have most likely experienced exploding head syndrome, a mysterious and poorly understood sleep disorder.
  • Exploding head syndrome (EHS) belongs to a family of sleep disorders known as parasomnias.
  • Other parasomnias include sleep paralysis and hypnic jerks – the cause of that unpleasant feeling of falling we sometimes experience when drifting off to sleep.
  • EHS has been known to medical professionals since at least 1876, and apparently the French philosopher and scientist René Descartes experienced it.

Triggers

  • On a typical night, as we transition from wakefulness into sleep, activity within the reticular formation of the brain is reduced.
  • The reticular formation is a set of brain structures located primarily in the brainstem and hypothalamus, that acts as an “on-off” switch for the brain.
  • In other words, life stress did not directly relate to EHS, but was related indirectly through first disrupting normal sleep patterns.

Is EHS dangerous?

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 47, Status: Authorised

Retrieved on: 
Wednesday, September 4, 2024
Blood, Cough, Aggression, Telbivudine, HCV, Thrombocythemia, European Medicines Agency, Medical Subject Headings, Hepatitis, Mental disorder, ALT, Skin, Suicide, Essential thrombocythemia, Chronic pain, Irritability, Risk, Hepatitis C, Patient, Language, Heart, Commission, Fatigue, Liver disease, Genotype, Hepatitis B virus, Joint, CHMP, HBeAg, Confusion, Hepatitis B, Alfa, Insomnia, Marketing, Anatomy, Anxiety, Lamivudine, Mania, Safety, European Commission, Itch, Overview, INN, Xeroderma, Select, Rash, CHC, Diarrhea, Viral, Syringe, Depression, Headache, Abdomen, CHB, IIA, Dizziness, International, DSM-IV codes, Serum, Liver, Thyroid disease, Bipolar disorder, Pain, Peginterferon-alfa, ATC, Infection, Growth, Hydroxycarbamide, Nausea, Medicine, Fever, Disease, Puberty, Polycythemia, Ribavirin, Thigh, Fibrosis, Hair loss, Vaccine

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 47, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 47, Status: Authorised

Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 11, Status: Authorised

Retrieved on: 
Wednesday, August 28, 2024
Hypertension, Back pain, Select, Dexamethasone, European Medicines Agency, Fatigue, Upper respiratory tract infection, Fever, International, Neutrophil, Diarrhea, Cancer, Human, Language, Commission, CD38, Medical Subject Headings, Multiple myeloma, Medicine, Febrile neutropenia, Disease, Nose, Immune system, ATC, European Commission, Pneumonia, Blood, Patient, Pharyngitis, Risk, Neutropenia, Marketing, Bronchitis, Infection, Lenalidomide, Overview, Insomnia, INN, IIA, CHMP, Periodic breathing, Anatomy, Bone marrow, Carfilzomib, Coombs test, Inflammation

Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 11, Status: Authorised